ILMN
BuyPremium GrowerAI neutralIllumina, Inc. · Healthcare · United States · $40.7B cap · $1.0B/day traded
$288.79 +3.3% · close 28 Oct · scored 29 Oct
Premium Grower: Strong business with the market behind it, priced at a premium.
Report expected 29 Oct: the next-year EPS estimate has risen 3.3% over the last 14 weeks, up 3 weeks running.
As of 29 Oct 2026, MoatMap's StockRank for Illumina, Inc. (ILMN) is 76/100, ranked against 24,000+ stocks in 35 markets (Quality 78, Value 19, Momentum 74, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Illumina is the dominant supplier of DNA sequencing instruments and consumables, with a large installed base that generates recurring consumables revenue. The shares are up about 133% this year to 52-week highs on recovering demand and hopes for Medicare coverage of multi-cancer detection tests. After that rally the valuation looks stretched, and insiders have sold about 1.4% of shares outstanding in the past 90 days, a large amount that tempers the bullish momentum.
ABOUT ILLUMINA, INC.
Read
Illumina, Inc. is the global leader in developing, manufacturing, and marketing integrated systems for large-scale analysis of genetic variation and function, providing sequencing and array-based instruments, reagents, and services. The company's formidable competitive moat stems from its proprietary sequencing technology, superior data quality, and extensive patent portfolio, which have established its platforms as the industry standard for genomic research and clinical applications worldwide. This dominant market position makes Illumina essential to advancements in precision medicine and biotechnology.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.6B | 4.5B | 4.4B | 4.3B | -1.8% | 4.5B | 4.6B | 4.9B | 6.5% |
| EPS | -28.00 | -7.34 | -7.69 | 5.47 | — | 5.36 | 6.05 | 6.93 | 12.5% |
| Shares | 158.0M | 159.0M | 159.0M | 153.0M | -3.2% | 151.0M | — | — | — |
| Debt | 3.6B | 2.3B | 2.6B | 2.6B | -10.4% | 2.5B | — | — | — |
| Equity | 6.6B | 5.7B | 2.4B | 2.7B | -25.6% | — | — | — | — |
| Op CF | 392.0M | 478.0M | 837.0M | 1.1B | 40.1% | 1.1B | — | — | — |
| Inv CF | -591.0M | -231.0M | -178.0M | -55.0M | — | — | — | — | — |
| Fin CF | 1.0B | -1.2B | -570.0M | -744.0M | — | — | — | — | — |
Above its 200-day average and 7% below its 52-week high.
Swung more than 63% of stocks we rank over the past year (50% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ILMN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ILMN | Illumina, Inc.(you) | $40.7B | 76 | Buy |
| A | Agilent Technologies, Inc. | $48.8B | 72 | Buy |
| IQV | IQVIA Holdings Inc. | $46.0B | 69 | Buy |
| WAT | Waters Corporation | $44.5B | 66 | Buy |
| IDXX | IDEXX Laboratories, Inc. | $44.1B | 65 | Hold |
| LH | Labcorp Holdings Inc. | $26.7B | 83 | Strong Buy |
| DGX | Quest Diagnostics Incorporated | $26.7B | 83 | Strong Buy |
| RVTY | Revvity, Inc. | $17.7B | 65 | Buy |
| MEDP | Medpace Holdings, Inc. | $18.7B | 90 | Strong Buy |
| CRL | Charles River Laboratories International, Inc. | $16.6B | 62 | Hold |
Peer medians: ROE -30.5% · P/E 27.2x · Gross margin 63.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.